APREA THERAPEUTICS, INC. (APRE): Price and Financial Metrics

APREA THERAPEUTICS, INC. (APRE): $5.71

0.19 (-3.22%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

Add APRE to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#192 of 405

in industry

APRE Price/Volume Stats

Current price $5.71 52-week high $8.85
Prev. close $5.90 52-week low $2.78
Day low $5.69 Volume 4,600
Day high $6.23 Avg. volume 32,283
50-day MA $6.55 Dividend yield N/A
200-day MA $4.68 Market Cap 31.01M

APRE Stock Price Chart Interactive Chart >


APREA THERAPEUTICS, INC. (APRE) Company Bio


Aprea Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Aprea Therapeutics serves customers in the United States and Sweden.


APRE Latest News Stream


Event/Time News Detail
Loading, please wait...

APRE Latest Social Stream


Loading social stream, please wait...

View Full APRE Social Stream

Latest APRE News From Around the Web

Below are the latest news stories about APREA THERAPEUTICS INC that investors may wish to consider to help them evaluate APRE as an investment opportunity.

Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

DOYLESTOWN, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today reported financial results for the three and nine months ended September 30, 2023, and provided a business update. “We are very pleased by the progress of our diversified programs this past quarter. Importantly, we presented initial clinical data from our Phase 1/2a study

Yahoo | November 9, 2023

Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways

Event featuring Fiona Simpkins, M.D. and Timothy A. Yap, MBBS, PhD, FRCP to take place on October 31, 2023 at 11:00 am ETDOYLESTOWN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced it will host a KOL event on Tuesday, October 31, 2023 at 11:00 am ET. The program will feature Dr. Fiona Simpkins, Perelman School of Medicin

Yahoo | October 24, 2023

Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio

DOYLESTOWN, Pa., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced highlights of two posters presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 14, 2023 in Boston, MA. The data in the posters include first-in-human clinical data from the ongoing Phase 1 dose escalation

Yahoo | October 16, 2023

Aprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

DOYLESTOWN, Pa., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced two poster presentations at the upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held on October 11-15, 2023, in Boston, MA. Aprea is in development with two assets. Its lead program is ATRN-119, a clinica

Yahoo | September 19, 2023

Aprea Announces Preclinical Data Supporting Highly Differentiated WEE1 Inhibitor, ATRN-1051, Relative To Other WEE1 Inhibitors

Demonstrating potential safety and efficacy of WEE1 inhibitor, ATRN-1051, in the treatment of ovarian cancer Company anticipates submitting an IND by the end of 2023 Data to be presented at an upcoming 2023 scientific conference, with KOL event planned for the fall DOYLESTOWN, Pa., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today annou

Yahoo | September 11, 2023

Read More 'APRE' Stories Here

APRE Price Returns

1-mo -7.75%
3-mo N/A
6-mo 7.13%
1-year 39.27%
3-year -93.39%
5-year N/A
YTD 21.49%
2023 -29.00%
2022 -88.47%
2021 -41.67%
2020 -89.28%
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!